Business Context and Reporting Period
This Form 8-K filing by Hancock Jaffe Laboratories, Inc. (HJLI) reports a corporate action effective November 30, 2020. The company, incorporated in Delaware and trading on The NASDAQ Stock Market LLC, implemented a reverse stock split to adjust its capital structure.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The primary financial data point disclosed relates to the capitalization adjustment:
- Pre-Split Outstanding Shares: 55,853,569
- Post-Split Outstanding Shares: 2,234,143
- Split Ratio: 1-for-25
- Authorized Shares: Remained unchanged at 250,000,000
Material Changes
The material change reported is the 1-for-25 reverse stock split of the Company's common stock. This action reduced the number of outstanding shares by a factor of 25 without changing the par value per share. Fractional shares resulting from the split were rounded up to the nearest whole share. Additionally, outstanding stock options and warrants were proportionally adjusted: the number of shares underlying these securities was reduced by a factor of 25, and exercise prices were increased by a factor of 25.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document focuses solely on the mechanics and execution of the reverse stock split, noting that trading began on a split-adjusted basis on November 30, 2020.
Investor Verification Checklist
- Verify the adjusted share count (2,234,143) in subsequent trading records.
- Confirm the adjusted exercise prices and share quantities for any held options or warrants.
- Review the Certificate of Amendment (Exhibit 3.1) for complete legal terms of the capitalization change.
- Check for any fractional share cash-out provisions, though this filing states fractional shares were rounded up.